CDK4 and neoplasm: Importantly, the triple combination completely blocked tumor regrowth during 8 weeks of treatment, while tumors treated with the standard double combination of fulvestrant and CDK4/6i started to expand after 6 weeks of treatment, suggesting outgrowth of resistant clones (Fig. 3E).